MetaCap

Apnimed Inc. (APMD)

NASDAQ: APMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD

16.09-1.16 (-6.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

APMD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$669.84M
EPS (TTM)
$13.34
52-week range
13.88 – 35.29
Day range
15.95 – 17.73
Volume / Avg
248.59K / 458.58K
Beta
—
Next earnings
Dec 8, 2026

52-week range

$13.88$35.29

APMD stock today

Apnimed (APMD) closed at $16.09 on Nov 20, down 6.70% (-$1.16), versus the S&P 500's 3.70% decline. At this level, APMD sits near the bottom of its 52-week range of $13.88 to $35.29: 54.4% below the high, set on Aug 18, 2026 and 15.9% above the low. Apnimed trades at 1.2x its trailing twelve-month earnings per share of $13.34.

The company is scheduled to report Sep/2026 results on Dec 8.

Summary generated from market data by MetaCap's automated system. Methodology

About Apnimed

Company profile

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Kevin Robert Lind
Headquarters
Cambridge, MA
Employees
112
IPO year
2026

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$50.00+210.75%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 8, 2026
Last reported (Sep/2026)
Dec 8, 2026
EPS actual vs est.
$-1.05 vs —

APMD news

All APMD news

Apnimed peers

Health Care sector
APMD peer companies
CompanyPrice% ChgMarket capCompare
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs APMD
LXRXLexicon Pharmaceuticals Inc.1.53-8.38%$681.21Mvs APMD
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs APMD
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs APMD
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs APMD
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs APMD
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs APMD
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs APMD

Indexes, lists and sector

Apnimed stock FAQ

What is Apnimed's stock price today?

APMD last traded at $16.09 as of Nov 20, 4:00 PM EST, down 6.70% on the day. Prices are delayed at least 15 minutes.

When is Apnimed's next earnings date?

Apnimed is expected to report earnings on Tuesday, December 8, 2026.

What is APMD's P/E ratio?

APMD trades at a trailing P/E ratio of 1.21.

Who is Apnimed's CEO?

Mr. Kevin Robert Lind is the chief executive officer of Apnimed Inc., which has about 112 employees.

What is the APMD 52-week high?

The 52-week high for APMD is $35.29 and the 52-week low is $13.88. The stock is currently 54.4% below its high.

Compare APMD